Journal Scans
Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial
First-Line Erlotinib vs Chemotherapy in EGFR+ NSCLC
R Rosell, E Carcereny, R Gervais, A Illiano, et al
20120025
2012 Jan 25
Lancet Oncol
Erlotinib Versus Standard Chemotherapy as First-Line Treatment for European Patients With Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial
Lancet Oncol. 2012 Jan 25;[Epub Ahead of Print], R Rosell, E Carcereny, R Gervais, A Illiano, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Background: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations. We aimed to assess the safety and efficacy of erlotinib compared with standard chemotherapy for first-line treatment of European patients with advanced EGFR-mutation positive NSCLC.Methods: We undertook the open-label, randomised phase 3 EURTAC trial at 42 hospitals in France,...
